Recent advances in mass spectrometry-based proteomic methods have allowed variable (V)-region peptide signatures to be derived from human autoantibodies present in complex serum mixtures. Here, we analysed the clonality and V-region composition of immunoglobulin (Ig) proteomes specific for the immunodominant SmD protein subunit of the lupus-specific Sm autoantigen. Precipitating SmD-specific IgGs were eluted from native SmD-coated ELISA plates preincubated with sera from six patients with systemic lupus erythematosus (SLE) positive for anti-Sm/RNP. Heavy (H)-and light (L)-chain clonality and V-region sequences were analysed by 2-dimensional gel electrophoresis and combined de novo database mass spectrometric sequencing. SmD autoantibody proteomes from all six patients with SLE expressed IgG1 kappa restricted clonotypes specified by IGHV3-7 and IGHV1-69 H-chains and IGKV3-20 and IGKV2-28 L-chains, with shared and individual V-region amino acid replacement mutations. Clonotypic sharing and restricted V-region diversity of systemic autoimmunity can now be extended from the Ro/La cluster to Sm autoantigen and implies a common pathway of anti-Sm autoantibody production in unrelated patients with SLE.
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Introduction
Anti-Smith (Sm) autoantibodies, discovered by Tan and Kunkel in 1966 as serum precipitins specific for patients with systemic lupus erythematosus (SLE), hold pride of place as founding members of the family of systemic autoantibodies targeting non-histone extractable nuclear antigens [1, 2] . Anti-Sm responses are present in 10% to 30% of SLE patients and form part of the American College of Rheumatology criteria (ACR) for the classification of SLE [3, 4] . The pathogenic significance of these autoantibodies is underlined by their appearance shortly before the clinical onset of SLE and the reported clinical associations with lupus nephritis and neuropsychiatric disease [5] [6] [7] . Sm autoantigens comprise a ring of 7 small nuclear ribonucleoprotein (snRNP) common core proteins (B, D1, D2, D3, E, F & G) with the snRNA passing through ring [8] . While SmB and SmD are the major targets of anti-Sm humoral autoimmunity, anti-SmD is considered to have the highest specificity for SLE [9] . Immune complexes of anti-Sm and snRNP particles are thought to perpetuate systemic autoimmunity by inducing type I interferon in plasmacytoid dendritic cells via combined Fc receptor and TOLL-like receptor 7 engagement [10, 11] .
Although the Sm protein-RNA antigenic complexes have been characterised in detail, the clonality and variable (V)-region composition of secreted (serum) human anti-Sm autoantibody proteomes have not been studied. Advances in mass spectrometric-based protein sequencing now allow heavy (H)-and (L)-chain V-region peptide maps to be generated for the first time from microgram quantities of autoantibodies derived from complex patient sera [12] . Recently, we have combined 2-dimensional gel electrophoresis (2-DE) of anti-Ro52/Ro60/La autoantibodies with de novo and database-driven V-region protein sequencing to show that humoral responses against these protein-RNA complexes are mediated by public (shared) autoreactive B cell clonotypes [13] [14] [15] . An early study reported oligoclonality and restricted V-region gene usage by anti-Sm hybridomas derived from MRL/lpr mice, raising the possibility of restricted anti-Sm clonality in human SLE [16] . In the present study, we characterise serum SmD autoantibody proteomes by high resolution mass spectrometric sequencing for the first time and find that the expression of these clinically important autoantibodies is dominated by unique sets of public clonotypes.
Patients and methods

Patients
Sera were collected from six patients with SLE who were positive for anti-Sm autoantibodies by commercial line blot immunoassay (Euroline ANA profile 5, Euroimmun, Lubeck, Germany). Demographic characteristics and serologic findings in the patients are shown in Table 1 . Control sera were taken from four healthy controls and three anti-SmD antibody-negative SLE patients positive for anti-ribosomal P, anti-RNP-A and antiRo52/Ro60/La antibodies respectively. Patients fulfilled at least four of the eleven ACR criteria for SLE [4] , including the presence of antibodies to double-stranded DNA by Farr assay (Trinity Biotech, Bray, County Wicklow, Ireland). The study was approved by the Clinical Ethics Committee of the Flinders Medical Centre.
Preparation and specificity analysis of anti-SmD autoantibodies
Anti-SmD IgGs were purified from ELISA plates (Maxi-Sorp; Nunc, Roskilde, Denmark) using a simple elution method. In brief, plates were coated with 1ug/ml of purified The activity and specificity of ELISA plate-purified Igs for SmD were determined by testing the starting sera (diluted 1:100), unbound fractions (normalized to each starting serum), and bound/eluted Igs (2.5 ug/ml) for reactivity against native SmD, native RNP-A (Arotec Diagnostics), and native Ro60 (Arotec Diagnostics) by ELISAs as described previously [13] .
Kappa and lambda distribution of bound anti-SmD Igs was determined by ELISA using specific rabbit anti-human kappa and anti-human lambda antisera (Dako, Denmark) detected by HRP-labelled donkey anti-rabbit antisera (Jackson ImmunoResearch, USA). Purified antiSm Igs were also tested for reactivity with native Sm antigen by indirect immunofluorescence of HEp-2 cells (Immunoconcepts, Sacramento, USA) and by counterimmunoelectrophoresis (CIEP) using rabbit thymus extract and anti-Sm and anti-RNP reference controls.
Two-dimensional gel electrophoresis (2-DE)
2-DE was performed as previously described [13] with the following modifications;
13-cm, non-linear immobilized pH 3-11 IPG strips (Bio-Rad, USA) were used in the first dimension and 8-15% gradient Criterion stain free TGX gels (Bio-Rad), at 300V using a
Criterion electrophoresis system (Bio-Rad) in the second dimension. Imaging was performed using a Gel Doc EZ Imager (Bio-Rad).
Mass spectrometry (MS)
In-solution digests were performed on plate-purified Igs, while in-gel digests were performed on H-and L-chain spots excised from 2-DE gels using Trypsin Gold (Promega, USA) as described previously [13] . Analysis of peptides was carried out using high-end-Q-TOF mass spectrometer (AB Sciex, USA) coupled to an Eksigent nanoLC 400 HPLC.
Samples were applied to a C18 trap (Eksigent, USA) and eluted onto a 15 cm C18 column (Nikkyos Technos, Japan) using a 2-40% acetonitrile gradient over 33 min. The instrument was operated in high sensitivity positive ion mode; charge state of +2 to +5 ions selected; with one MS scan followed by 20 MS/MS scans. At least two technical and biological replicates were performed for each sample.
Protein sequence data analysis
MS data was analysed using Peaks Studio v7.0 software (Bioinformatics Solution Inc, Canada) using the following parameters: 2 ppm; product ion error tolerance of 0.01 Da; precursor charge state of +2 to +4; database search performed against a combined ImMunoGeneTics (IMGT) (http://www.imgt.org) and the Uniprot 2010-06 database as described previously [14] .
Results
Purification of anti-SmD IgGs from anti-Sm-positive sera
To purify anti-Sm autoantibodies for analysis of clonality by 2-DE and mass spectrometric sequencing, we eluted antibodies bound to native SmD-coated ELISA plates from the sera of six SLE subjects with mixed anti-Sm/RNP/Ro60 specificities.
Monospecificity of eluted IgGs for anti-SmD was confirmed by testing starting sera, unbound and eluted fractions on individual SmD/RNP-A/Ro60 ELISAs (Fig.1A) . In addition, eluted
IgGs gave a speckled nuclear immunofluorescence pattern with nucleolar and chromosomal sparing on HEp-2 cells (Fig. 1B) , and formed a precipitin line of identity to an anti-Sm reference serum and partial identity to an anti-RNP reference serum on CIEP, confirming reactivity with native Sm antigen (Fig. 1C) . Assessment of clonality of plate-purified antiSmD IgGs by reduced 2-DE revealed two H-chain clusters of spots ranging from pI 6.4-7.6
(identified as IGHV3-7 on gel plug digests) and pI 8-9.2 (IGHV1-69) together with two distinct clusters of kappa (K) L-chain spots ranging from pI 6.6-7.6 (IGKV2-28) and pI 8.2-9.2 (IGKV3-20) (Fig. 2) . Similar charge variants have been reported for clonotypic anti-Ro60 and anti-La autoantibodies and are presumed to arise from post-translational modifications [13, 15] . IgG tryptic peptides were detected by mass spectrometry of elutes from SmD-coated ELISA plates treated with normal human sera (n = 4) and SmD antibody-negative lupus sera with specificities for ribosomal P, RNP-A and Ro52/Ro60/La antibodies respectively (data not shown).
SmD-reactive clonotypic
Discussion
This study reveals that secreted anti-SmD autoantibody proteomes in unrelated patients with SLE are dominated by IgG1 kappa-restricted clonotypes specified by two The proteomic workflow developed herein utilised a simple ELISA plate-based method to purify anti-SmD autoantibodies from as little as one millilitre of complex SLE sera, followed by combined electrophoretic analysis and de novo and database-driven mass spectrometric sequencing. The methodology requires as little as 20 micrograms of native or recombinant antigen for antibody isolation and sequencing of V-region clonotypic peptides;
can be completed within a few days; and be used to determine V-region signatures for any serum autoantibody or humoral anti-viral response for which purified antigen or epitope is available.
sequencing times by days, sample size remains limited by the complexity of immunoglobulin bioinformatics analysis. The high-end-Q-TOF mass spectrometry used herein performs higher mass accuracy protein sequencing and better protein coverage than Orbitrap mass spectrometry used in previous studies, making it more suited to de novo peptide sequencing [23] . High-mass accuracy mass spectrometric L-chain constant region sequencing enables direct analysis of kappa/lambda restriction at the protein level, as opposed to standard immunochemical methods that may vary with antigen purity and specificity of anti-L-chain antibodies. Our finding of an absolute kappa restriction of purified anti-SmD IgGs as indicated by a unique kappa peptide profile by L-chain sequencing and kappa-specific antiSmD solid phase immunoassay, differs from a 1980s study that used a different, antigen source and anti-L-chain [24] .
We anticipate that the discovery of shared anti-Sm autoantibody clonotypes will open new pathways of research for this prototypic systemic autoantigen, with unique V-region clonotypic peptides detected by mass spectrometric sequencing being potential novel biomarkers of anti-Sm autoantibody production. For example, mutated Sm-specific V-region clonotypic peptides might be used in targeted mass spectrometric platforms such as multiple reaction monitoring to quantitate specific V-region peptides in complex serum mixture, or to 10 monitor expression of anti-Sm clonal turnover in patients undergoing treatment [14, 25] . A priority will be to sequence linked RNP/Sm autoantibody populations to test whether intermolecular sharing of autoreactive clonotypes holds true for the Sm/RNP autoantigen cluster. A long-term goal will be to correlate secreted autoantibody proteomes derived by mass spectrometry with Sm-specific B cell and plasma cell receptor repertoires in blood and tissues.
In conclusion, we use a novel proteomic workflow to determine the molecular signatures of anti-SmD autoantibodies from unrelated patients with SLE. Remarkably, the response is restricted to the same H-and L-chain immunoglobulin families and shares Vregion amino acid replacement mutations, a finding of pathognomonic and diagnostic significance for anti-Sm immunity in lupus. 
